Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) whose sole drug, Soliris, goes for upward of $400,000 a year, tumbled 8%. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares after opening at $174.85 moved to $177.07 on last trade day and at the end of the day closed at $159.79. Company price to sales ratio in past twelve months was calculated as 20.45 and price to cash ratio as 20.94. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) showed a negative weekly performance of -8.84%.
Biogen Idec (NASDAQ:BIIB) EVP Douglas E. Williams sold 3,505 shares of Biogen Idec stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $352.29, for a total value of $1,234,776.45. Biogen Idec Inc (NASDAQ:BIIB) shares fell -8.22% in last trading session and ended the day on $318.53. BIIB return on equity ratio is recorded as 23.30% and its return on assets is 16.90%. Biogen Idec Inc (NASDAQ:BIIB) yearly performance is 80.42%.
Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) reported financial results for the three and twelve months ended December 31, 2013. The company’s net product revenue for the three months ended Dec. 31, 2013, was $33.3 million, an increase of 95% from the $17.1 million in net product revenue recognized for the three months ended December 31, 2012. Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares moved down -9.54% in last trading session and was closed at $21.52 while trading in range of $21.32 – $23.90 – Celldex Therapeutics, Inc. (NASDAQ:CLDX) year to date (YTD) performance is -11.11%.
A record number of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) call contracts were traded during the busy trading session. There were 2.7 call contracts traded for each put contract yielding a 0.37 put/call ratio where 3,997 put and 10,796 call contracts exchanged hands. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) weekly performance is -3.24%. On last trading day company shares ended up $26.01. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) distance from 50-day simple moving average (SMA50) is 1.80%. Analysts mean target price for the company is $30.43.